Van Den Berg Management I Inc. Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Van Den Berg Management I Inc. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 133.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,588 shares of the medical research company's stock after purchasing an additional 4,907 shares during the quarter. Van Den Berg Management I Inc.'s holdings in Thermo Fisher Scientific were worth $4,468,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Stonegate Investment Group LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after buying an additional 18 shares in the last quarter. Semus Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after acquiring an additional 18 shares in the last quarter. Bangor Savings Bank lifted its holdings in Thermo Fisher Scientific by 6.0% in the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock worth $174,000 after buying an additional 19 shares during the period. Eagle Rock Investment Company LLC lifted its stake in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after purchasing an additional 19 shares during the period. Finally, KRS Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after buying an additional 20 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TMO shares. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Evercore ISI dropped their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. UBS Group reduced their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Raymond James reiterated an "outperform" rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Finally, Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Five investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $610.27.

Thermo Fisher Scientific Trading Up 1.1 %

TMO stock traded up $4.50 during trading on Tuesday, hitting $425.84. The company had a trading volume of 1,185,591 shares, compared to its average volume of 2,190,828. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average of $485.08 and a 200-day moving average of $525.48. The stock has a market cap of $160.75 billion, a PE ratio of 25.76, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $5.11 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.